Abstract:Influenza virus infection is an ongoing health and economic burden causing epidemics with pandemic potential, affecting 5–30% of the global population annually, and is responsible for millions of hospitalizations and thousands of deaths each year. Annual influenza vaccination is the primary prophylactic countermeasure aimed at limiting influenza burden. However, the effectiveness of current influenza vaccines are limited because they only confer protective immunity when there is antigenic similarity between the selected vaccine strains and circulating influenza isolates. The major targets of the antibody response against influenza virus are the surface glycoprotein antigens hemagglutinin (HA) and neuraminidase (NA). Hypervariability of the amino acid sequences encoding HA and NA is largely responsible for epidemic and pandemic influenza outbreaks, and are the consequence of antigenic drift or shift, respectively. For this reason, if an antigenic mismatch exists between the current vaccine and circulating influenza isolates, vaccinated people may not be afforded complete protection. There is currently an unmet need to develop an effective “broadly-reactive” or “universal” influenza vaccine capable of conferring protection against both seasonal and newly emerging pre-pandemic strains. A number of novel influenza vaccine approaches are currently under evaluation. One approach is the elicitation of an immune response against the “Achille’s heel” of the virus, i.e. conserved viral proteins or protein regions shared amongst seasonal and pre-pandemic strains. Alternatively, other approaches aim toward eliciting a broader immune response capable of conferring protection against the diversity of currently circulating seasonal influenza strains.In this review, the most promising under-development universal vaccine approaches are discussed with an emphasis on those targeting the HA glycoprotein. In particular, their strengths and potential short-comings are discussed. Ultimately, the upcoming clinical evaluation of these universal vaccine approaches will be fundamental to determine their effectiveness against preventing influenza virus infection and/or reducing transmission and disease severity.

Research Progress in Broad Neutralizing Antibodies and Universal Vaccines Against Influenza A Virus

Research Progress on Drug-Resistance of Influenza Virus to Neuraminidase Inhibitors

Progress and perspectives of universal influenza vaccine

Broad neutralizing antibody-based strategies to tackle influenza

Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head

Classification of influenza A virus and its value for research of universal influenza vaccine and broad-spectrum neutralization antibody

Advances in Nucleic Acid Universal Influenza Vaccines

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Progress towards the Development of a Universal Influenza Vaccine

Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus

Progress on adenovirus-vectored universal influenza vaccines

Flu Universal Vaccines: New Tricks on an Old Virus

Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function

Research and Development of Universal Influenza Vaccines.

The race toward a universal influenza vaccine: Front runners and the future directions

[Research and development technology platform and research progress of universal influenza vaccine]

Generation and Characterization of Monoclonal Antibodies Against the Hemagglutinin of H3N2 Influenza A Viruses.

Towards a universal influenza vaccine: different approaches for one goal

Approaches in broadening the neutralizing antibody response of the influenza vaccine

Advances in Development and Application of Influenza Vaccines

Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens